41X Stock Overview
A biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Ardelyx, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.20 |
| 52 Week High | US$9.12 |
| 52 Week Low | US$3.64 |
| Beta | 0.91 |
| 11 Month Change | -23.00% |
| 3 Month Change | -19.92% |
| 1 Year Change | 15.41% |
| 33 Year Change | 354.16% |
| 5 Year Change | -31.69% |
| Change since IPO | -71.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| 41X | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -30.1% | -1.0% | -0.2% |
| 1Y | 15.4% | -18.7% | 7.8% |
Return vs Industry: 41X exceeded the German Biotechs industry which returned -18.7% over the past year.
Return vs Market: 41X exceeded the German Market which returned 7.8% over the past year.
Price Volatility
| 41X volatility | |
|---|---|
| 41X Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 41X's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 41X's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 267 | Mike Raab | www.ardelyx.com |
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder.
Ardelyx, Inc. Fundamentals Summary
| 41X fundamental statistics | |
|---|---|
| Market cap | €1.01b |
| Earnings (TTM) | -€69.04m |
| Revenue (TTM) | €239.56m |
4.4x
P/S Ratio-15.4x
P/E RatioIs 41X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 41X income statement (TTM) | |
|---|---|
| Revenue | US$251.85m |
| Cost of Revenue | US$85.54m |
| Gross Profit | US$166.31m |
| Other Expenses | US$238.89m |
| Earnings | -US$72.58m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 66.03% |
| Net Profit Margin | -28.82% |
| Debt/Equity Ratio | 79.0% |
How did 41X perform over the long term?
See historical performance and comparison